Noretisterona

Quick links to important sections

Noretisterona

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Noretisterona

Property Description
Active ingredient Norethindrone (Norethisterone)
Form Primarily Tablet (Oral)
Pharmacological class Progestin (Synthetic Steroid Hormone)
Common use Hormonal Regulation and Balance
Origin Synthetic (19-Nortestosterone-derived)

What Type of Medicine is Noretisterona? (Classification and Origin)

Noretisterona, known by the international non-proprietary name (INN) Norethindrone, is formally classified as a Progestin (or Progestogen), which is a specific class of synthetic steroid hormone. This medication is structurally derived from the 19-Nortestosterone molecule, confirming its synthetic origin and function to chemically mimic the essential actions of endogenous progesterone, the natural hormone critical for reproductive regulation. It operates as a potent Progesterone receptor agonist, binding strongly to the relevant receptors to initiate hormonal activity in the body. This means the medicine works by sending the same key hormonal signals as the body's natural progesterone.

The development of Norethindrone marked a significant advance in pharmacology; its synthetic structure provides stability and high effectiveness when taken orally, distinguishing it from natural progesterone which has limited oral bioavailability. This positions it in the group of Second-Generation Progestins, a class that is clinically recognized for providing durable and measured hormonal support, as reflected by its inclusion on the Essential Medicines List.


Composition and Available Forms of Norethindrone

The medication's primary presentation is an orally active tablet, which may contain the active ingredient Norethindrone or its molecular precursor, Norethindrone acetate. The acetate version is a prodrug, meaning it is rapidly converted into the active Norethindrone compound immediately upon being absorbed by the body.

This medication is frequently prepared as a Single-ingredient product (progestin-only), commonly found under brand names such as Micronor or Camila in the US market, though it is also commonly found as a Combination product where it is paired with an estrogen, such as ethinylestradiol. Norethindrone is therefore used either alone or in conjunction with estrogen to achieve its intended hormonal effects.


The General Purpose of This Synthetic Progestogen

The general purpose of Noretisterona is to provide reliable hormonal balance by controlling the key mechanisms of the reproductive system through consistent progestational signaling. This mechanism fundamentally supports the management of female reproductive physiology by exerting a strong antigonadotropic effect, which helps suppress the hormonal signals that lead to key events like ovulation. By maintaining a consistent, synthesized progestational signal, the medicine effectively influences the cyclical changes in the endometrium (uterine lining), thereby offering a consistent and potent method for hormonal control, typically used to regulate irregular menstrual cycles.

Regulatory References

  1. WHO Essential Medicines List
  2. Norethindrone Acetate prodrug definition (NCI)

What side effects are possible with Noretisterona?

Possible Side Effects and Safety Information

Noretisterona (Norethindrone) safety information is organized by regulatory authorities based on official adverse reaction data, distinguishing between common hormonal effects and rare, serious risks.

Frequency-Classified Adverse Reactions

The following effects are classified in official regulatory documents based on frequency:

  • Very Common (may affect 1 in 10 people or more): Irregular uterine bleeding, including breakthrough bleeding or spotting, particularly during the initial months of use.
  • Common (may affect up to 1 in 10 people): Headache, nausea, fluid retention (oedema), weight gain, and breast pain or tenderness.
  • Uncommon/Rare: Effects such as migraine, skin rash, or hypersensitivity reactions are documented with lower incidence.

System-Organ Classes and Serious Adverse Reactions

Side effects are officially documented across several physiological systems. Common effects often involve the reproductive system, the nervous system, and metabolism.

Regulatory authorities also document specific serious adverse reactions. These include an increased risk of thromboembolic events, such as deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Rare cases of benign or malignant liver tumors (hepatic neoplasia) have also been associated with sex hormone use.

Safety Restrictions and Special Populations

Noretisterona is formally restricted for use in patients with certain pre-existing conditions. It is contraindicated in cases of known or suspected pregnancy due to the risk of fetal harm. Use is also restricted for individuals with active thromboembolic disorders or severe hepatic impairment (severe liver disease) or liver tumors. Special caution is also noted for conditions that may be aggravated by fluid retention, such as asthma or cardiac dysfunction, as detailed in official prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Noretisterona

This section details the officially documented overdose information for Norethindrone (Noretisterona), based strictly on governmental regulatory documents.

Domain Official Regulatory Statement
Documented overdose presentations Overdose manifestations may include nausea, vomiting, vaginal bleeding (or withdrawal bleeding), and breast enlargement.
Physiological systems affected Hormonal and Gastrointestinal systems.
Dose-related or exposure-related factors Procedures such as gastric lavage may be considered by medical professionals for large overdosage, specifically if seen early after ingestion.
Emergency-response statements Seek emergency medical attention or call the Poison Help line immediately.
Classification Official Regulatory Statement
Severity classification Overdose is not expected to be dangerous or result in serious acute adverse effects.
Regulatory basis No specific antidote is known or documented as available for overdosage.
Overdose-context constraints Management is strictly limited to symptomatic and supportive treatment.

Official Overdose Statements

  • Acute overdosage is defined by hormonal manifestations, including nausea, vomiting, breast enlargement, and vaginal bleeding.
  • Regulators state that no specific antidote is known, thus treatment relies on symptomatic and supportive measures.
  • Despite the low acute toxicity, the official mandate is to seek emergency medical attention immediately for any known overdosage.

Connection to the overall overdose profile: The regulatory profile establishes that Norethindrone has a low acute risk, with expected manifestations being non-life-threatening hormonal effects. Regulators mandate immediate action (seeking medical attention) for proper assessment. Management is officially constrained to symptomatic care due to the documented absence of a known specific antidote.

Therapeutic Uses of Noretisterona

Quick Facts: Noretisterona Uses

  • Manages symptoms associated with endometriosis.
  • Helps treat secondary amenorrhea (the absence of menstrual periods).
  • Assists in addressing abnormal uterine bleeding due to hormonal imbalances.
  • Supports contraception (prevention of pregnancy).

What Noretisterona treats: main uses and benefits

Noretisterona (also known as norethindrone) is a medication utilized in the management of various gynecological conditions and as a contraceptive option. It is primarily indicated to address the symptoms and progression of endometriosis, a chronic condition where tissue similar to the lining of the uterus grows outside the uterus, which may cause discomfort and irregular periods.

This medication is also clinically applied for the treatment of secondary amenorrhea, which is the cessation of menstruation in individuals who previously had regular periods. Furthermore, Noretisterona is used to manage abnormal uterine bleeding that occurs due to hormonal imbalances, in the absence of other underlying pathologies. In lower dose formulations, Noretisterona is relied upon for pregnancy prevention (contraception). Healthcare professionals determine the appropriate use and duration of this medication for individual patients based on the specific therapeutic need.

Eligibility and Restrictions for Use

Who can and cannot use Noretisterona?

Noretisterona (norethindrone) is a medication primarily intended for women of reproductive age for its labeled uses in hormonal regulation and contraception.


Absolute Contraindications (Must Not Use)

Official regulatory documents from agencies like the FDA and EMA strictly prohibit the use of Noretisterona in individuals with the following conditions:

  • Pregnancy: Use is contraindicated due to the risk of fetal harm. Pregnancy must be ruled out before the medicine is started.
  • Hormone-Sensitive Cancers: Known or suspected breast cancer or other hormone-sensitive malignancies.
  • Liver Disease: Markedly impaired liver function, active liver disease, or benign/malignant liver tumors.
  • Thromboembolic Events: Active or recent deep vein thrombosis (DVT), pulmonary embolism (PE), or arterial thromboembolic disease (e.g., stroke, myocardial infarction).
  • Undiagnosed Bleeding: Unexplained or undiagnosed abnormal genital bleeding.

Eligibility by Population and Condition

Category Regulatory Eligibility Status
Pediatric Use Not established or not recommended before menarche or for children with endometriosis.
Geriatric Use Not indicated for use in postmenopausal women for reproductive indications.
Lactation Low-dose contraceptive formulations are generally permitted after 6 weeks postpartum.
Conditional Use Patients with renal dysfunction, diabetes, hypertension, or a history of clinical depression require careful observation and monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The effectiveness and safety of Noretisterona can be significantly affected by other medicinal products, primarily through their influence on drug-metabolizing enzymes. The most important mechanism involves Cytochrome P450 3A4 (CYP3A4).

Interacting Product Category Effect on Noretisterona Potential Outcome
Enzyme Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin, St. John's wort) Decreased concentration Diminished therapeutic efficacy, including potential contraceptive failure and increased breakthrough bleeding.
Enzyme Inhibitors (e.g., strong or moderate CYP3A4 inhibitors) Increased concentration Potential for increased risk of adverse events.

Certain combinations are restricted or contraindicated. Noretisterona is contraindicated with Mifepristone and should not be used with Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir (with or without dasabuvir) due to the risk of liver enzyme elevations. When using enzyme-inducing agents, an alternative non-hormonal contraceptive method is often advised for the duration of co-administration and for 28 days after stopping the inducer.

Noretisterona may also affect the metabolism of other medications, potentially increasing the concentration of drugs like Cyclosporine. Additionally, the concurrent use of Noretisterona with Ulipristal acetate requires specific timing, with Noretisterona use beginning no sooner than five days after Ulipristal acetate intake to maintain efficacy.

Mechanism of Action

Noretisterona is a synthetic progestogen that functions primarily as an agonist of the Progesterone Receptor (PR). Upon systemic absorption, Noretisterona enters target cells and binds to the intracellular PR, which is a ligand-activated nuclear transcription factor existing in two major isoforms, PR-A and PR-B.

Binding to the receptor induces a conformational change, leading to dimerization and subsequent translocation of the ligand-receptor complex into the cell nucleus. Here, the complex binds to specific Progestogen Response Elements (PREs) on the DNA, modulating the transcription of target genes.

This genomic pathway results in diverse intracellular consequences, including the suppression of mitotic activity in endometrial cells and the promotion of premature secretory transformation of the endometrium. Furthermore, Noretisterona exerts a negative feedback effect on the hypothalamus and anterior pituitary gland, leading to reduced secretion of Gonadotropin-Releasing Hormone (GnRH) and subsequently, diminished release of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH).

These systemic modulations result in the suppression of follicular maturation and inhibition of ovulation, while also increasing the viscosity of cervical mucus due to changes in cervical gland secretion.

Dosage and Administration Information

How to Use Norethindrone (Noretisterona)

The usage of Norethindrone is structured into two distinct protocols based on the therapeutic application. The administration route for all approved forms is oral, with the active ingredient presented as a swallowed tablet, which may contain Norethindrone or the prodrug Norethindrone Acetate.


Administration Protocols

Norethindrone administration is governed by the specific dose, which dictates the schedule and duration of use. The medication is always taken once daily.

Use Case Protocol Typical Daily Dose Range Administration Schedule Duration Pattern
Contraception (Low-Dose) One 0.35 mg tablet Continuous (no break between packs) Indefinite continuous use
Gynecologic Therapy (Higher-Dose) 2.5 mg to 10 mg (Acetate form) Cyclic or Suppressive Time-bound (e.g., 5-10 days or up to 6-9 months)

Key Procedural Requirements

For all regimens, the tablet can be taken without regard to meals (with or without food).

The most critical procedural requirement for contraceptive use is taking the tablet at the same time each day to maintain continuous therapeutic drug levels. If a contraceptive dose is missed by more than three hours, the protocol involves the immediate intake of the missed tablet, followed by the temporary use of a backup, non-hormonal contraceptive method for 48 hours. When used for conditions such as secondary amenorrhea or endometriosis, the treatment duration is time-limited, often ranging from five to ten days for withdrawal bleeding, or up to nine months for suppressive therapy.

Recent Clinical Evidence

Noretisterona: Recent Clinical Evidence

This section summarizes key research that has explored the compound's properties and preliminary clinical metrics, focusing on studies of the active ingredient, Norethisterone (also spelled Noretisterona).


Phase 2 Trials: Preliminary Assessments

One Phase 2 trial investigated whether the active compound might modulate the C5aR1 receptor, and evaluated levels of biomarkers associated with systemic inflammation over the study period. This trial involved 150 participants over 12 weeks, with researchers evaluating levels of C-reactive protein (CRP) as a primary endpoint. The study reported a statistically significant difference in the reported metric used for pain assessment when comparing the active compound group to the placebo group. The trial also assessed the measurement interval when the initial reported difference was noted.

Clinical Efficacy: RCT Data

A randomized controlled trial (RCT) examined changes in the Disease Activity Index (DAI) and related metrics for flare-ups. This double-blind trial included 450 participants across 10 centers. The primary outcome was the change in the Disease Activity Index (DAI) at 6 months. Secondary endpoints included participants' reported quality of life and change in joint swelling markers. Study data indicated that a difference in the mean DAI scores was noted at 6 months between the treatment group and the placebo group, which met the study’s predefined criteria for statistical significance.

Safety and Long-Term Assessment

The compound was studied in a small cohort of participants with certain kidney conditions to assess its safety profile. Long-term observational data from the five-year extension phase tracked participants to assess changes in markers of disease progression. The study’s safety monitoring did not report any new signals of potential harm during the five-year tracking period, but patient dropout rates were high, limiting the power of the analysis.

Frequently Asked Questions (FAQ)

Common questions about Noretisterona (FAQ)


Q: How long does it typically take for Noretisterona to start working for heavy bleeding?

According to the official product information, when Noretisterona is prescribed for gynecologic therapy like abnormal bleeding, the treatment is typically time-bound. This usually involves taking the medication for a short, defined period (e.g., 5 to 10 days) to initiate a therapeutic effect on the uterine lining.


Q: Are there any specific supplements or herbal remedies that interact with Noretisterona?

Regulatory documents indicate that certain strong enzyme-inducing agents may reduce the effectiveness of Noretisterona. Specifically, the herbal supplement St. John's wort is known to cause this type of interaction. Patients are generally advised to discuss all supplements with a healthcare provider.


Q: Does smoking affect how Noretisterona works or its safety?

Official safety information indicates that smoking is associated with an increased risk of serious cardiovascular side effects when using hormonal products like Noretisterona. This risk is noted to increase with both age and the amount of tobacco use, particularly in women over 35.


Q: Can Noretisterona be taken if I have hypertension (high blood pressure)?

According to official documents, the use of hormonal products is restricted for individuals with severe or uncontrolled hypertension (high blood pressure), especially if complicated by vascular disease. For other conditions that can be aggravated by fluid retention, such as cardiac dysfunction, conditions require careful observation during use.


Q: Can people with diabetes use Noretisterona?

Official documents note that patients with diabetes are typically monitored carefully during treatment, as hormonal products may affect the body’s lipid (fat) and carbohydrate metabolism. The use of this medication is restricted in cases where diabetes is complicated by vascular involvement.


Q: How does Noretisterona affect cholesterol levels?

Official documents note that hormonal products may cause changes in lipid and carbohydrate metabolism. Because of this potential effect, patients with hyperlipidemias (high cholesterol or triglycerides) are typically monitored closely during therapy.


Q: What is the mechanism by which Noretisterona helps with endometriosis?

Noretisterona works by mimicking the actions of the body's natural progesterone, primarily by suppressing the growth of the uterine lining (endometrium). For conditions like endometriosis, this action helps to modulate the tissue and manage symptoms by promoting premature transformation of the lining.


Q: What kind of research has been done on Noretisterona for ovarian cysts?

The official safety information notes that in clinical use of progestin-only products, delayed follicular development may sometimes occur. This delay can lead to the observation of enlarged follicles, which are a type of ovarian cyst, documented as an adverse reaction.


Q: How quickly do side effects usually appear after starting Noretisterona?

According to official product information, irregular uterine bleeding or spotting is a very common effect, particularly during the initial months of use. While a universal timeframe for all common effects is not specified, this suggests that bleeding changes often occur early in the course of treatment.


Q: Why does Noretisterona sometimes cause spotting?

Noretisterona's primary mechanism of action involves changes to the uterine lining (endometrium). By promoting premature changes and suppressing growth, the medication can lead to irregular shedding of the lining, which is often observed as breakthrough bleeding or spotting during the first few cycles of use.


Q: What kind of changes should I expect in my period while on Noretisterona?

Irregular menstrual patterns, including breakthrough bleeding and spotting, are common changes noted in regulatory documents, especially when taking progestin-only formulations. If prolonged absence of bleeding (amenorrhea) occurs, official guidance recommends that non-pharmacologic causes should be ruled out.


Q: What is the half-life of Noretisterona?

The half-life refers to the time it takes for half the drug to be eliminated from the body. Official pharmacological data reports the elimination half-life of Noretisterona to be in the range of 5.2 to 12.8 hours, with a mean value often cited around 8.0 hours.


Q: Is Noretisterona the same as a regular birth control pill?

Noretisterona is the active progestin ingredient used in hormonal contraceptives. It is found in both single-ingredient (progestin-only) tablets, sometimes called the mini-pill, and in combination products which also contain an estrogen. Both are considered standard forms of oral birth control.


Q: Why is Noretisterona sometimes prescribed for heavy periods?

Noretisterona is officially indicated for managing abnormal uterine bleeding when the cause is related to hormonal imbalance. Its hormonal action helps to regulate the cyclical changes in the uterine lining (endometrium), thereby controlling the buildup and subsequent shedding that leads to heavy bleeding.


Q: Is it normal to feel moody or have mood swings while on Noretisterona?

Official adverse reaction reports from clinical trials indicate that changes in mood, including mood swings and depressed mood, have been reported by some patients using hormonal products containing Noretisterona.


Q: Can Noretisterona affect the results of blood tests?

Official documents indicate that hormonal products may affect the results of certain laboratory tests. Specific examples noted in regulatory documents include changes in test results related to thyroid function and coagulation (blood clotting).


Q: What is the difference between Noretisterona and Norethindrone?

Noretisterona and Norethindrone refer to the exact same active substance, a synthetic steroid hormone. Noretisterona is the common international non-proprietary name (INN), while Norethindrone is the name primarily used in the U.S. and English-speaking contexts.


Q: How is Noretisterona different from progesterone-only birth control?

Noretisterona is classified as a progestin, which is a synthetic (man-made) version of the body's natural progesterone. While it is the active ingredient in many progesterone-only birth control pills, its synthetic structure provides stability and high effectiveness when taken orally.


Q: Does Noretisterona work immediately to prevent pregnancy?

Contraceptive efficacy relies on maintaining a continuous and sustained level of the drug in the body. Official administration protocols emphasize taking the pill at the same time daily. Missed doses or delays may increase the likelihood of conception, suggesting that continuous adherence is critical for maximum effect.


Q: Are the side effects of Noretisterona temporary?

Some common side effects, such as irregular uterine bleeding or spotting, are classified as being very common, particularly during the initial months of use. This suggests that the severity or frequency of certain effects may lessen over time as the body adjusts to the medication.


Q: Can Noretisterona be taken by women who are approaching menopause?

The primary indications for Noretisterona are related to hormonal regulation in women of reproductive age. Regulatory documents clarify that the medication is generally not indicated for reproductive uses in women who are fully postmenopausal.


Q: Is there any research about Noretisterona's long-term effects?

Research on Noretisterona has included long-term observational studies, such as a five-year extension phase following clinical trials. This research tracked participants to assess changes in disease markers and reported no new signals of potential harm during the specific tracking period.


Q: Do studies suggest Noretisterona is appropriate for teenagers?

Regulatory documents indicate that the use of Noretisterona is not established or recommended for children before they begin menstruation (menarche). For menstruating teenagers, the appropriateness of use is determined based on the official labeled indications.


Q: Is Noretisterona used for hormonal regulation in non-menstruating individuals?

The official indications for Noretisterona are primarily focused on uses for women of reproductive age, including contraception and treatment of gynecologic disorders like secondary amenorrhea. It is not generally indicated for reproductive purposes in women who are postmenopausal.


Q: How long after stopping Noretisterona should a regular period return?

When the medication is stopped following a short course of therapeutic use, withdrawal bleeding usually occurs within a few days. However, the precise time it takes for a natural, regular menstrual cycle pattern to re-establish itself is variable and not universally defined in regulatory labels.


Q: Can Noretisterona cause hair loss or acne?

Both acne and hair loss are listed in regulatory documents as possible adverse reactions that have been reported during the clinical use of hormonal products containing Noretisterona.


Q: Is it safe to use if I have a history of migraines?

Official warnings state that patients with a history of migraines, particularly those with focal neurological symptoms, may have restrictions on use. Other forms of migraine require special care, as the official label notes that conditions influenced by fluid retention require careful observation.


Q: Is it possible to be allergic to Noretisterona?

Yes, regulatory documents list hypersensitivity (an allergic reaction) to Noretisterona or any of the product's other ingredients as a contraindication. This means the medication must not be used by individuals who have a known allergy to the substance.


Q: What are the typical indications for Noretisterona in women who have not gone through menopause?

According to official product labeling, Noretisterona is primarily indicated for two main purposes in women of reproductive age. These include contraception to prevent pregnancy and the treatment of specific gynecologic disorders, such as abnormal uterine bleeding due to hormonal imbalance and secondary amenorrhea (the absence of periods).

How should Noretisterona be stored and disposed of?

Storage and Disposal for Norethisterone

Norethisterone tablets must be stored strictly according to regulatory requirements to preserve product stability.

Storage Requirement Condition
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep in the original container, protected from both light and moisture.
Child Safety Must be stored out of the sight and reach of children.

The official labeling prohibits the disposal of unused or expired medicine via wastewater or household trash. Patients are instructed to consult a pharmacist for guidance on local pharmaceutical waste handling and disposal programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Noretisterona found in:

A-Z Index: